| |
|
|
|
|
| January 17,
2010 | ISSUE NUMBER 130 VOL 7 |
Studies
Antidepressants Might Not Be A Sure Shot
A new JAMA study reveals that antidepressants might not have as strong an effect on people with less severe cases of depression. How this will affect the pharma industry, which once made heaps of cash with drugs like Prozac, remains to be seen.
Deals
Novartis Bids Big on Alcon
It’s just a few days into the new year and already a potential megamerger has been announced: Novartis offered $39 billion for complete control of ocular drug manufacturer Alcon.
Global
EU Pharma Policy 2010: Resolutions? Yes. Solutions? Maybe.
There was an air of hope and confidence among officials and diplomats at the turn of the year in Brussels — or at least there would have been if anyone had been at work.
Podcast
Pharma Unplugged Episode #3:
George Koroneos and Reid Paul cover the top five trends and news stories in the pharmaceutical industry for 2009.
New & Noteworthy
Change Agent
FDA Commissioner Margaret Hamburg has a history of health advocacy and a clear mandate to transform the agency. But can she succeed where others have failed?
|
 |
|  Greenleaf Health hired Daniel G. Schultz, former Director of the Center for Devices and Radiological Health at FDA, as senior vice president, medical devices and combination products.
// CrystalGenomics and CG Pharmaceuticals appointed Eric M. Nelson vice president of business development.
// Pieris named Stephen S. Yoder CEO.
// Centene Corporation appointed Toni Simonetti senior vice president of public affairs.
// BIO Ventures for Global Health named Melinda Moree chief executive officer of the global health non-profit.
//
|
Jan 21–22, 2010 Bio/Pharmaceutical Forum on Optimizing the Use of Complex Data Assets,
Philadelphia, PA
Jan 25–26, 2010 Pharmaceutical Forum on Strategic Sourcing and Procurement,
Philadelphia, PA
Feb 8–9, 2010 3rd Annual Clinical Trial Forecasting and Budgeting, Philadelphia, PA
Feb 23 –25, 2010 BIO-Windhover/Pharmaceutical Strategic Outlook, New York, NY
April 12–14, 2010 19th Annual Partnerships in Clinical Trials, Orlando FL
|
|
|
|
 |
|
 |
|
 |
| Is Novartis making a smart move in purchasing Alcon? |
|
|
|
|
You
are subscribed to %%list.name%% as %%emailaddr%%. To unsubscribe
from this list click
here.
To
ensure delivery to your Inbox, please add %%email.list%% to your
address book. If you need help doing this, click
here.
Advanstar Communications provides certain customer contact data (such as customers' names, addresses, phone numbers and e-mail addresses) to third parties who wish to promote relevant products, services and other opportunities which may be of interest to you. If you do not want Advanstar Communications to make your contact information available to third parties for marketing purposes, simply call (toll free) 1-866-529-2922 at any time, or fax us at 1-218-740-6417. Outside the U.S., please phone 1-218-740-6395. Contact us by mail at Advanstar Communications Inc., 131 West First St., Duluth, MN 55802-2065, USA.
|
|
